Relmacabtagene Autoleucel CD19 CART Therapy for Adults with Heavily-Pretreated Relapsed/Refractory Large B-Cell Lymphoma in China

Introduction Prognosis for relapsed and refractory large B-cell lymphoma (r/r LBCL) is poor, and treatment remains challenging. Relmacabtagene autoleucel (relma-cel) is a CD19-directed 4-1BB/CD3z chimeric antigen receptor T cell (CAR-T) product manufactured in China. RELIANCE study is the first CAR-...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.3557-3557
Hauptverfasser:	Song, Yuqin, Ying, Zhitao, Yang, Haiyan, Guo, Ye, Li, Wenyu, Zou, Dehui, Zhou, Daobin, Wang, Zhao, Zhang, Mingzhi, Wu, Jianqiu, Liu, Hui, Zhang, Pian, Yang, Su, Zhou, Zisong, Zheng, Hongxia, Zhu, Jun
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!